DHTKD1 and renal carcinoma: Therefore, we developed the Ad‐CAIXpromotor‐AIM2 that was an E1B55kD deletion with the E1A gene controlled by CAIXpromotor, armed with the AIM2 gene to enhance the therapeutic efficacy of renal cancer.